Furthermore, the clinical response in RA patients treated with RTX correlated positively with the depletion of the pre‐switch memory B cells (CD19+IgD+CD27+CD95−), which is the increased cell population in response to anti‐TNF‐α therapy.89 This evidence concerns the gene CD19 and rheumatoid arthritis.